Nabors Industries (NYSE:NBR) has been given a “BBB-” credit rating by Morningstar. The credit rating agency’s “BBB-” rating suggests that the company is a moderate default risk. They also issued a negative credit outlook for the company and gave their stock a three star rating. Nabors Industries Ltd. (NYSE:NBR) belongs to Basic Materials sector. Its net profit margin is 2.40% and weekly performance is 0.12%. On last trading day company shares ended up $24.48. Nabors Industries Ltd. (NYSE:NBR) distance from 50-day simple moving average (SMA50) is -9.42%.
Wells Fargo & Co (NYSE:WFC) has for the first time decided to expand the use of ETFs and Bond Funds to create some good quality portfolios. As per the information made available by the company, it used to invest into individual securities including bonds in order to generate significant returns under Compass Advisory Program’s fixed income accounts. The market has started offering more challenges and options now; hence, the company has introduced ETFs as well. Now the investment managers will be able to invest various mutual funds and exchange traded funds. It will not only generate various opportunities to earn extra cash, but also provide flexibility, easy trading and extra liquidity. Wells Fargo & Company (NYSE:WFC) shares moved up 0.71% in last trading session and ended the day at $52.31. WFC’s return on assets is 1.40%. Wells Fargo & Company (NYSE:WFC) quarterly performance is 1.26%.
Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX)’s shares increased 4.30% to $5.34. Salix Pharmaceuticals, Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) on Aug. 11 announced that the Food and Drug Administration (FDA or Agency) has informed Salix that the supplemental New Drug Application (sNDA) for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29, 2014. On 16 September, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares moved up 0.97% and was closed at $5.20. PGNX EPS growth in last 5 year was 12.50%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) year to date (YTD) performance is -2.44%.
Recro Pharma, Inc. (NASDAQ:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, announced a clinical strategy update following findings from a prespecified interim analysis conducted on the initial half of patients who completed enrollment in the Company’s REC-13-012 trial. The trial is a double blind, placebo-controlled study of intranasal dexmedetomidine, Dex-IN, in the treatment of acute post-operative pain following bunionectomy surgery on Post Op Day 0. While analgesia and a reduction in opioid use were observed in a subset of patients, the study is not expected to reach statistical significance in its current design. As a result, the Company plans to close this study and launch a revised study starting in Q4 2014. The Company will evaluate Dex-IN 50 mcg versus placebo in management of post-op pain starting Post Op Day 1 after bunionectomy surgery. Note that there were no serious adverse events observed in the REC-13-012 trial. Recro Pharma, Inc. (NASDAQ:REPH) ended the last trading day at $3.46. Company weekly volatility is calculated as 12.88% and price to cash ratio as 0.96. Recro Pharma, Inc. (NASDAQ:REPH) showed a weekly performance of 2.97%.
Masco Corporation (NYSE:MAS) got rating of Zacks Rank #3 (Hold). Masco Corporation (NYSE:MAS) shares moved up 1.26% in last trading session and ended the day at $24.18. MAS Gross Margin is 28.00% and its return on assets is 5.00%. Masco Corporation (NYSE:MAS) quarterly performance is 11.33%.